Literature DB >> 902457

Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology.

J S Dutcher, J M Strong, S V Lucas, W K Lee, A J Atkinson.   

Abstract

The pharmacokinetics of procainamide (PA) and N-acetylprocainamide (NAPA) were compared in 3 normal subjects after simultaneous intraveous injection of PA and NAPA-13C. The distribution kinetics of both compounds were modeled with a 3-compartment mamillary system, and it was found that their steady-state distribution volumes were not significantly different, averaging 1.41 L/kg for PA and 1.46 L/kg for NAPA. However, the intercompartmental clearances of NAPA were slower than those of PA. In these normal subjects, the average elimination t1/2 and total elimination clearance for PA were 2.5 hr and 589.8 ml/min, and for NAPA were 6.2 hr and 233.7 ml/min. Mean renal clearances of PA (346.7 ml/min) and of NAPA (199.5 ml/min) exceeded the usual rate of glomerular filtration, which suggests that both compounds are eliminated in part by renal tubular secretion. All subjects were phenotypic rapid acetylators of isoniazid and converted approximately one fourth of the administered PA dose to NAPA-12C. The fate of 15.4% of the administered PA and 14.5% of the administered NAPA-13C was not determined.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 902457     DOI: 10.1002/cpt1977224447

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

1.  An initial slope method for model structure: independent estimation of the elimination rate constant of a metabolite.

Authors:  V K Piotrovskii
Journal:  J Pharmacokinet Biopharm       Date:  1991-06

2.  Metabolite formation pharmacokinetics: rate and extent of metabolite formation determined by deconvolution.

Authors:  M D Karol; S Goodrich
Journal:  Pharm Res       Date:  1988-06       Impact factor: 4.200

3.  Population pharmacokinetic modeling of plasma Δ9-tetrahydrocannabinol and an active and inactive metabolite following controlled smoked cannabis administration.

Authors:  Cristina Sempio; Marilyn A Huestis; Susan K Mikulich-Gilbertson; Jost Klawitter; Uwe Christians; Thomas K Henthorn
Journal:  Br J Clin Pharmacol       Date:  2020-01-20       Impact factor: 4.335

4.  Ranitidine and procainamide absorption.

Authors:  A Somogyi; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

Review 5.  Application of stable labelled drugs in clinical pharmacokinetic investigations.

Authors:  M Eichelbaum; G E von Unruh; A Somogyi
Journal:  Clin Pharmacokinet       Date:  1982 Nov-Dec       Impact factor: 6.447

Review 6.  Therapeutic drug monitoring of antiarrhythmic agents.

Authors:  J E Brown; D G Shand
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

7.  Analysis of the contributions of permeability and flow of intercompartmental clearance.

Authors:  G P Stec; A J Atkinson
Journal:  J Pharmacokinet Biopharm       Date:  1981-04

8.  Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.

Authors:  J J Lima; D R Conti; A L Goldfarb; W J Tilstone; L H Golden; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

9.  Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man.

Authors:  A Somogyi; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

10.  Population pharmacokinetics of procainamide from routine clinical data.

Authors:  T H Grasela; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.